transitioning from semaglutide to tirzepatide Switching Tirzepatide: A Provider's Guide Semaglutide & Tirzepatide for Weight

Glucagon-like peptide-1 (GLP-1) in the integration of neural and endocrine responses to stress

Patients should be counseled to report severe abdominal pain immediately Gallbladder disease : Increased risk of cholelithiasis and cholecystitis, likely related to rapid weight loss Hypoglycemia : Risk is low when used alone but increases when combined with insulin or sulfonylureas Thyroid C-cell tumors : Based on rodent studies, these agents carry a boxed warning and are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 Acute kidney injury : Can occur, particularly with dehydration from gastrointestinal side effects Diabetic retinopathy complications : Semaglutide may worsen diabetic retinopathy in patients with diabetes, particularly with rapid improvement in glucose control Severe gastrointestinal disease : Use with caution in patients with gastroparesis or severe gastrointestinal disease

Patients with certain genetic profiles may experience faster nausea onset or better tolerance when eating shortly after injection, while others benefit from waiting

To add volume back to the face, people often use cosmetic procedures like fillers or procedures that boost collagen

It is not approved for any human therapeutic, diagnostic, or clinical application